Search | Clinical Trials Finder

Conditions: Acne
Interventions: Acne mRNA vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 79
States / cities: Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more

Conditions: Metastatic Breast Cancer
Interventions: Decision-making support tool; Other
Lead sponsor: University of Rochester; Other
Eligibility: 65 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more

Conditions: Lichen Simplex Chronicus
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Anaheim, California • Fremont, California • Miami, Florida + 9 more

Conditions: Skin Aging, Weight Loss
Interventions: Revival Soy Dietary Supplement; Behavioral
Lead sponsor: Physicians Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Lupus Nephritis
Interventions: Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 11
States / cities: Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Breast Cancer, Lung Cancer, Prostate Cancer
Interventions: inactivated influenza vaccine and the 23- valent pneumococcal vaccine, inactivated influenza vaccine and the PPV23 vaccine (Pneumovax); Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis
Interventions: Guselkumab, Placebo for guselkumab, Etanercept; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 10
States / cities: Palo Alto, California • San Diego, California • Macon, Georgia + 7 more

Conditions: Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions: Efgartigimod PH20 SC; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Beverly Hills, California • Orange, California + 15 more

Conditions: Herpes Simplex
Interventions: famciclovir; Drug
Lead sponsor: Novartis; Industry
Eligibility: 1 Month to 1 Year
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 3 more

Conditions: Breast Neoplasm, Osteoporosis, Postmenopausal
Interventions: Resistance Exercise, Flexibility Training; Behavioral
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 50 Years to 90 Years · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Colorectal Cancer, Breast Cancer, Cervical Cancer
Interventions: Coach Training (COACH), Printed Educational Materials (PEM); Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 50 Years to 74 Years
Enrollment: 1,106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Skin Aging, Skin Wrinkling
Interventions: PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo); Drug
Lead sponsor: Kalpna Kay Durairaj, MD, FACS; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Diaper Rash
Interventions: Not listed
Lead sponsor: Kimberly-Clark Corporation; Industry
Eligibility: Up to 12 Months
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Systemic Lupus Erythematosus
Interventions: atorvastatin; Drug
Lead sponsor: The Center for Rheumatic Disease, Allergy, & Immunology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Psoriasis
Interventions: Apremilast (CC-10004), Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 35 more

Conditions: Atopic Dermatitis
Interventions: Dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 40
States / cities: Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 35 more

Conditions: Breast Cancer
Interventions: Observational cohort; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 70 Years and older · Female only
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 4
States / cities: Bangor, Maine • Boston, Massachusetts • Providence, Rhode Island

Conditions: Chlorhexidine Allergy, Infection, Rash
Interventions: Chlorhexidine gluconate; Drug
Lead sponsor: Celeste Chandonnet; Other
Eligibility: 36 Weeks to 48 Weeks
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dermatitis, Atopic
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 28
States / cities: Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more

Conditions: Diabetic Foot Ulcer, Pressure Ulcer, Venous Leg Ulcer, Trauma Injury, Skin Tear, Chronic Ulcer
Interventions: RD1 System; Device
Lead sponsor: RedDress Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Butler, Pennsylvania

Conditions: Breast Cancer
Interventions: ARV-471, Abemaciclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Palo Alto, California • San Francisco, California • Tampa, Florida + 11 more

Conditions: Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions: Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector; Combination Product
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Palo Alto, California • Sacramento, California • Aurora, Colorado + 15 more

Conditions: Juvenile Idiopathic Arthritis
Interventions: comparison of types of sleep disordered breathing; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 6 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

Evaluation of a Patient-Centered Decision-Making Support Tool for Older Adults With Advanced Breast Cancer and Their Care Partners

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)

Effect of Revival Soy on Weight Loss and Skin, Hair, and Nails in Premenopausal Women

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection

Strength Training for Older Breast Cancer Survivors

Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

BM Characterization Pilot

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Elevate! : An Elderly Breast Cancer Cohort Study

Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

A Prospective, Open Label, Multicenter Trial for Evaluating the Efficacy of Treating and Managing Wounds in Elderly Population in Specialized Nursing Facilities Using RD1

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis